Senate Panel Backs Penalizing Drugmakers for their 340B Contract Pharmacy Actions

The Democratic-controlled Senate Appropriations Committee says it's pleased with HRSA's response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

U.S. Senate appropriators say they’re happy with the federal government’s response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Biden Moves to End Trump’s Limits on HHS Guidance Including for 340B

The Biden administration wants to repeal ex-President Trump's regulation that has helped to cast doubt on the authority of 340B program guidance.

The Biden administration yesterday formally announced that it wants to repeal a regulation issued during ex-President Trump’s last days in office that has helped to cast doubt on the authority of federal health care guidance, including for the 340B program.

Read More »

Appeals Court Affirms Dismissal of Privacy Lawsuit Involving 340B Contract Pharmacy

A federal appeals court affirmed the legality of Walgreens' handling of customers' personal identifying information for 340B purposes.

A federal appeals court has affirmed a lower court’s dismissal of a lawsuit alleging that Walgreens’ internal transfer of pharmacy customers’ personal identifying information (PII) for 340B drug discount drug purposes violates South Carolina and federal privacy laws.

Read More »

BMS Tells 340B Entities It Has Lifted Purchasing Limits on Leukemia Drug

BMS's Celgene subsidiary has lifted purchasing limits for 340B covered entities and non-340B buyers on its injectable acute myeloid leukemia (AML) drug Vidaza.

Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.

Please Login or Become a

Read More »

During Crucial Oral Arguments in AstraZeneca 340B Suit, Feds Urge Judge to Take a Fresh Look at Their Case

A federal district judge in Delaware heard arguments yesterday in AstraZeneca's 340B contract pharmacy lawsuit against the government.

A federal government lawyer told a judge during a hearing yesterday that the government’s case against AstraZeneca and other drug companies that deny 340B drug discounts when covered entities use contract pharmacies is “in a very different posture” than it

Read More »

340B ADR Rule Is Fundamentally Defective, PhRMA Tells Federal Court

PhRMA told a federal court in Baltimore, Md., that none of the federal government's legal arguments "can hide the fundamental defects" in the 340B ADR rule.

Pharmaceutical Research and Manufacturers of America told a federal district judge last week that the federal government has failed to refute PhRMA’s contention that the regulation establishing the 340B administrative dispute resolution (ADR) process “is unconstitutional, procedurally defective, and relies

Read More »

340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look

Ted Slafsky
If Congress changes hands during next year’s mid-term elections, expect a renewed effort to place significant restrictions on the 340B program, 340B Report Publisher and CEO Ted Slafsky predicts.

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

Read More »

News Alert: Judge Denies Sanofi Stay Against 340B ADR Proceedings, as Stakeholders Brace for Coming Whirlwind of Crucial Decisions in 340B Cases

A federal district judge yesterday denied Sanofi's emergency request for a stay against 340B ADR proceedings, in part because she said she will rule in Sanofi's 340B contract pharmacy lawsuit on or before Nov. 5.

A federal district judge in New Jersey has denied drug manufacturer Sanofi’s emergency motion for a stay against 340B administrative dispute resolution (ADR) proceedings—in part because she said she will hand down her decision in Sanofi’s 340B contract pharmacy lawsuit

Read More »

In Important Development, HHS Close to Rescinding Trump-era Rule that Undercuts its Sub-Regulatory Power

HHS is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including for 340B.

The U.S. Health and Human Services Department (HHS) is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including those for the 340B program.

Please Login or

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report